The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Lorenza Mittempergher, Midas M. Kuilman, Andrei Barcaru, Benjamin Nota, Leonie J.M.J. Delahaye, M. William Audeh, Denise M. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, W. Fraser Fraser Symmans, Ruixiao Lu, Minetta C. Liu, Rita Nanda, Laura Esserman, Laura van 't Veer, Annuska M. Glas, I-SPY 2 Investigators
Institutions: Agendia (Netherlands), Agendia (United States), University of California, San Francisco, Buck Institute for Research on Aging, The University of Texas MD Anderson Cancer Center, Genomic Health (United States), Mayo Clinic, University of Chicago Medical Center, UCSF Helen Diller Family Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281678686